NEW YORK (GenomeWeb News) — Inverness Medical Innovations today said that the required waiting period has expired on its proposed offer to buy Biosite without the need for additional information.
The company said on May 18 it would acquire Biosite for $92.50 share after a protracted bidding war with Beckman Coulter ended in its favor.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.